United States Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The US pharmaceutical market presents strong commercial opportunities across the industry. Total US pharmaceutical sales reached USD347.2bn in 2013 - more than three times the size of its nearest rival Japan. The US boasts the largest individual markets across the three core su[...]

Slovenia Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Slovenia is facing deflationary pressures on consumer prices, which will impact pharmaceutical spending - especially as an increasing proportion of high-value drugs is met by co-payments. We have therefore downwardly revised our pharmaceutical forecast for 2014. A high budget d[...]

Myanmar Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: While the current medical gap will attract some foreign investors into Myanmar, we highlight that the lack of basic infrastructure and political instability will potentially affect the growth of the economy. Headline Expenditure Projections ? Pharmaceutical sales: M[...]

Kazakhstan Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Kazakhstan's healthcare sector suffers from a lack of trained medical professionals and the inherent difficulties of providing infrastructure and access to healthcare in such a large country. However, the government continues to show its commitment to improving healthcare as it[...]

Ireland Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The US government and the OECD recent proposals to discourage corporate inversion pose downside risk to the rate of M&A deals that opt to establish their new headquarters' domicile in Ireland, although the megatrend of consolidation within the pharmaceutical industry, including[...]

Iran Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market to contract sharply in US dollar terms. While [...]

Central America Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Costa Rica and Panama will continue to outperform other Central American countries, namely El Salvador, Guatemala, Honduras, Nicaragua and Belize. The business-friendly environment, high percapita medicine spending and strong consumer demand still present strong revenue-generat[...]

Bangladesh Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: We consider Bangladesh's commitment to another round of spending on the development of healthcare, information technology, infrastructure, energy production, education, agriculture and food security and transportation in fiscal year 2014/2015 as a sound investment. While we are[...]

Austria Pharmaceuticals and Healthcare Report Q4 2014

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: BMI has upwardly revised its pharmaceutical and healthcare forecasts for Austria, reflecting the country's improving economic prospects and attractiveness of these sectors in particular. The United States Commerce department has listed Austria as one of the most attractive coun[...]

Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Published in ; US $ 600 Onwards; Publisher: Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-t[...]